Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model

Annals of Neurology

Volumn 47, Issue 6, 2000, Pages 739-747

  Holtzman, David M ^a   Fagan, Anne M ^a   Mackey, Brian ^a   Tenkova, Tanya ^a   Sartorius, Leah ^a   Paul, Steven M ^b   Bales, Kelly ^b   Ashe, Karen Hsiao ^c   Irizarry, Michael C ^d   Hyman, Bradley T ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE ASSOCIATION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SENILE PLAQUE; TISSUE PREPARATION;

EID: 0034123538     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8     Document Type: Article

References (59)

1. Plump AS, Breslow JL. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr 1995;15:495-518
2. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630
3. Pitas RE, Boyles JK, Lee SH, et al. Lipoproteins and their receptors in the central nervous system. J Biol Chem 1987;262: 14352-14360
4. Rebeck GW, Alonzo NC, Berezovska O, et al. Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp Neurol 1998;149:175-182
5. LaDu MJ, Gilligan SM, Lukens SR, et al. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem 1998; 70:2070-2081
6. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981
7. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923
8. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein ε4 allele in patients with Alzheimer's disease. Ann Neurol 1993; 34:752-754
9. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele decreases risk of late onset Alzheimer disease. Nat Genet 1994;7:180-184
10. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653
11. Greenberg SM, Rebeck GW, Vonsattel JPG, et al. Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995;38:254-259
12. Premkuman DRD, Cohen DL, Hedera P, et al. Apolipoprorein E-ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996;148:2083-2095
13. Greenberg SM, Briggs ME, Hyman BT, et al. Apolipoprotein E ε4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996;27:1333-1337
14. Olichney JM, Hansen LA, Galasko D, et al. The apolipoprotein E ε4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996;47:190-196
15. Nicoll JAR, Burnett C, Love S, et al. High frequency of apolipoprotein E ε2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997;41:716-721
16. Greenberg SM. Vonsattel J-PG, Segal AZ, et al. Association of apolipoprotein E ε2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998;50:961-965
17. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 1997;17:263-264
18. Holtzman DM, Bales KR, Wu S, et al. In vivo expression of apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J Clin Invest 1999;103:R15-21
19. 717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999;96:15233-15238
20. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102
21. Irizarry MC, McNamara M, Fedorchak K, et al. APPsw transgenic mice develop age-relaied Aβ deposits and neuropil abnormalities, but no neuronal loss in CAl. J Neuropathol Exp Neurol 1997;56:965-973
22. Carlson GA, Borchelt DR, Dake A, et al. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet 1997;6:1951-1959
23. Sun Y, Wu S, Bu G, et al. GFAP-apoF. transgenic mice: astrocyte specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci 1998;18:3261-3272
24. Wozniak DF, Brosnan-Watters C, Nardi A, et al. MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning. Brain Res 1996;707:165-179
25. Carlsen J, de Olmos JS. A modified cupric-silver technique for the impregnation of degenerating neurons and their processes. Brain Res 1981;208:426-431
26. Cavalieri B. Geometria degli indivisibili. Torino, Italy: Unione Tipografico, 1966
27. West MJ. New stereological methods for counting neurons. Neurobiol Aging 1993;14:275-285
28. Johnson-Wood K, Lee M, Motter R, et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1997; 94:1550-1555
29. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke 1987;18:311-324
30. Frautschy SA, Yang F, Irizarry M, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pachol 1998; 152:307-317
31. Neumann MA. Combined amyloid vascular changes and argyrophilic plaques in the central nervous system. J Neuropathol Exp Neurol 1960;19:370-382
32. Jellinger K. Cerebrovascular amyloidosis with cerebral hemorrhage. J Neurol 1977;214:195-206
33. Calhoun ME, Burgermeister P, Phinney AL, et al. Neuronal overexpression ot mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 1999;96:14088-14093
34. Hsiao KK, Borchelt DR, Olson K, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995;15:1203-1218
35. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995;373:523-527
36. Irizarry MC, Soriano F, McNamara M, et al. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997;17:7053-7059
37. Joachim CL, Duffy LK, Morris JH, Selkoe DJ. Protein chemical and immunocytochemical studies of meningovascular β-amyloid protein in Alzheimer's disease and normal aging. Brain Res 1988;474:100-111
38. Prelli F, Castano E, Glenner GG, Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 1988;51:648-651
39. Miller DL, Papayannopoulos IA, Styles J, et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 1993; 301:41-52
40. Roher AE, Lowenson JD, Clarke S, et al. β-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:10836-10840
41. Murrell J, Farlow M, Ghetti B, Benson M. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991;254:97-99
42. Lannfelt L, Boigdanovic N, Appelgren H, et al. Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neurosci Lett 1994;168:254-256
43. Knowles RB, Wyart C, Buldyrev SV, et al. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci USA 1999; 96:5274-5279
44. Yankner BA, Mesulam M-M. Beta-amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med 1992;325:1849-1855
45. LaDu MJ, Falduto MT, Manelli AM, et al. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 1994; 269:23404-23406
46. Naslund J, Thyberg J, Tjernberg LO, et al. Chatacterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron 1995;15:219-228
47. Wisniewski T, Lalowski M, Golabek AA, et al. Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 1995;345: 956-958
48. Russo C, Angelini G, Dapino D, et al. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc Natl Acad Sci USA 1998;95:15598-15602
49. Permanne B, Perez C, Soto C, et al. Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 1997; 240:715-720
50. Beffert U, Aumont N, Dea D, et al. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Mol Brain Res 1999;68:181-185
51. Yang DS, Small DH, Seydel U, et al. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 1999;90:1217-1226
52. Ma J, Yee A, Brewer HB, et al. Amyloid-associated proteins alpha-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994;372: 92-94
53. Castano EM, Prelli F, Wisniewski T, et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J 1995;306:599-604
54. Sanan DA, Weisgraber KH, Russel SJ, et al. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 1994;94:860-869
55. Evans KC, Berger EP, Cho C-G, et al. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 1994;92:763-767
56. Wood SJ, Chan W, Wetzel R. Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 1996;35:12623-12628
57. Namba Y, Tomonaga M, Kawasaki H, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res 1991;541:163-166
58. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperon protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-238
59. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:2892-2897